Fostroxacitabine bralpamide hydrochloride is under clinical development by Medivir and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fostroxacitabine bralpamide hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fostroxacitabine bralpamide hydrochloride overview

fostroxacitabine bralpamide (MIV-818) is under development for the treatment of metastatic hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma. The drug candidate is administered through the oral route as a capsule. It is a prodrug of troxacitabine. It is liver-targeted nucleoside prodrug. It acts by targeting DNA polymerase.

Medivir overview

Medivir is a pharmaceutical company. It is engaged in drug discovery and development of treatments for cancer.The company offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid leukemia. Medivir also provides products in partnership with other pharmaceutical companies for the disease areas of hepatitis C and labial herpes. The company’s products are in Phase I and phase II development stages. It conducts research and development in the areas of infectious diseases, bone disorders and cancer. The company operates through a research unit in Huddinge, Sweden. Medvir is headquartered in Huddinge, Sweden.

For a complete picture of Fostroxacitabine bralpamide hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.